CK Life Sciences Int'l (Holdings) Inc (CK Life) is a company that operates in healthcare research and development, pharmaceutical innovations, nutraceuticals, and agriculture-related businesses. The company serves industries such as healthcare, agriculture, and food manufacturing, providing products like cancer vaccines, pain management solutions, nutraceuticals, plant protection products, and salt. It collaborates with partner companies and academic institutions worldwide for research and development.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

CK Life is actively engaged in healthcare research and development with a focus on accelerating the pace of development and commercialization of pharmaceutical products. The company aims to bring more effective health solutions to the community by intensifying its research and development efforts. CK Life Sciences is also working on nurturing organic growth from its existing commercial businesses to support R&D activities. The company is pursuing a three-pronged strategy that includes intensifying R&D, facilitating the growth of commercial businesses, and enhancing corporate development efforts. The company is involved in developing novel cancer vaccines and has made significant advancements in AI-enabled cancer vaccine design platforms. The R&D unit of CK Life is responsible for conducting healthcare research and development activities, ensuring the sustainability of R&D efforts, and managing the commercialization of pharmaceutical products. The company has filed a Hong Kong Original Grant Patent application and a U.S. provisional patent application for its TROP2 vaccines. The company has several pipeline products, including Seviprotimut-L, TTX-MC138, TTX-siMYC, TTX-siPD-L1, TTX-RIGA, UIO-524, UIO-525, UIO-526, Halneuron, SP16, CKLS202, CKLS118, CKLS126, and CKLS121. CK Life has a research partnership with XtalPi to co-develop an AI-enabled cancer vaccine design platform. In FY2025, the company spent HKD321.6 million on R&D, which as a percentage of revenue, stood at 5.9% and grew 26.2% YoY.